Novartis India Ltd

Novartis India Ltd Share Price Today: Live Updates & Key Insights

Get insights on Novartis India Ltd’s fundamentals, financials, shareholding, peer comparison, corporate actions & performance. Track key metrics, price trends & market sentiment for informed decisions. Explore all data at Motilal Oswal.

Novartis India Ltd Share Price Chart

Novartis India Ltd Fundamentals

Traded Volume: 11,837

Market Cap(Cr): 1,660

Avg Traded Price 700.03

1 Year return -1.49%

Upper Circuit 698.2

Lower Circuit 668.4

P/E TTM 19.00

P/B Ratio 43.00

Traded Value(Cr) 79.57

EPS TTM 43.170

Book value 43.170

Dividend 3.00%

Novartis India Ltd Share Price Performance

Shows the percentage change in stock price over different time periods

This section highlights Novartis India Ltd stock price performance across key timeframes, including 1-week, 1-month, 3-month, Year-To-Date (YTD), and 1-year returns. It provides insights into the Novartis India Ltd share price history, short-term movements, long-term trends, and overall investor sentiment

1W -6.23%

1M -6.85%

3M -12.85%

1Y -1.49%

YTD 0.00%

Novartis India Ltd Traded Volume Movement

Shows the trading volume over different time periods

This section highlights Novartis India Ltd daily and average traded volumes, offering insights into investor activity and market liquidity. Higher volumes than average often indicate rising interest, news impact, or shifting market sentiment

Yesterday 21747.00

Day Before Yesterday 21747.00

1W Avg null

1M Avg null

3M Avg null

Novartis India Ltd Technical Details

Novartis India Ltd technical indicators, such as support and resistance levels and pivot points, are calculated based on historical price and volume trends. These metrics help traders anticipate possible price movements and make informed trading decisions.

Support 1 823

Support 2 815

Support 3 805

Pivot Point : 834

Resistance 1 842

Resistance 2 853

Resistance 3 861

Novartis India Ltd Corporate Actions

Novartis India Ltd corporate actions include dividends, bonus issues, stock splits, and key company updates that may affect share price and investor sentiment. This section provides timely details on past and upcoming actions, including ex-date, record date, and payout ratio - helping investors make informed decisions based on Novartis India Ltd’s capital allocation strategies.

All

Ex-Date 23-Jul-2025 Type D Description 25.00/share@500.00% Record Date 23-Jul-2025 Ratio 500.00

Ex-Date 23-Jul-2024 Type D Description 25.00/share@500.00% Record Date 07-Nov-2025 Ratio 500.00

Ex-Date 20-Jul-2023 Type D Description 10.00/share@200.00% Record Date 07-Nov-2025 Ratio 200.00

Ex-Date 20-Jul-2023 Type D Description 37.50/share@750.00% Record Date 07-Nov-2025 Ratio 750.00

Ex-Date 20-Jul-2022 Type D Description 10.00/share@200.00% Record Date 07-Nov-2025 Ratio 200.00

Ex-Date 17-Aug-2021 Type D Description 10.00/share@200.00% Record Date 07-Nov-2025 Ratio 200.00

Ex-Date 29-Jul-2020 Type D Description 10.00/share@200.00% Record Date 07-Nov-2025 Ratio 200.00

Ex-Date 31-Jul-2019 Type D Description 10.00/share@200.00% Record Date 07-Nov-2025 Ratio 200.00

Ex-Date 18-Jul-2018 Type D Description 10.00/share@200.00% Record Date 07-Nov-2025 Ratio 200.00

Ex-Date 07-Dec-2017 Type T Description /share@% Record Date 07-Nov-2025 Ratio

Ex-Date 19-Jul-2017 Type D Description 10.00/share@200.00% Record Date 07-Nov-2025 Ratio 200.00

Ex-Date 21-Jul-2016 Type T Description /share@% Record Date 07-Nov-2025 Ratio

Ex-Date 21-Jul-2016 Type D Description 10.00/share@200.00% Record Date 22-Jul-2016 Ratio 200.00

Ex-Date 14-Jul-2015 Type D Description 10.00/share@200.00% Record Date 07-Nov-2025 Ratio 200.00

Ex-Date 16-Jul-2014 Type D Description 5.00/share@200.00% Record Date 07-Nov-2025 Ratio 200.00

Ex-Date 16-Jul-2013 Type D Description 10.00/share@200.00% Record Date 07-Nov-2025 Ratio 200.00

Ex-Date 18-Jul-2012 Type D Description 10.00/share@200.00% Record Date 07-Nov-2025 Ratio 200.00

Ex-Date 18-Jul-2011 Type D Description 10.00/share@200.00% Record Date 07-Nov-2025 Ratio 200.00

Ex-Date 21-Jul-2010 Type D Description 10.00/share@200.00% Record Date 07-Nov-2025 Ratio 200.00

Ex-Date 08-Jul-2009 Type D Description 10.00/share@200.00% Record Date 07-Nov-2025 Ratio 200.00

Ex-Date 07-Jul-2008 Type D Description 10.00/share@200.00% Record Date 07-Nov-2025 Ratio 200.00

Ex-Date 22-Mar-2007 Type D Description 10.00/share@200.00% Record Date 23-Mar-2007 Ratio 200.00

Dividends

Announcement Date 23-Jul-2025 Ex Dividend Date 23-Jul-2025 Dividend(%) 500

Announcement Date 23-Jul-2024 Ex Dividend Date 23-Jul-2024 Dividend(%) 500

Announcement Date 20-Jul-2023 Ex Dividend Date 20-Jul-2023 Dividend(%) 750

Announcement Date 20-Jul-2023 Ex Dividend Date 20-Jul-2023 Dividend(%) 200

Announcement Date 20-Jul-2022 Ex Dividend Date 20-Jul-2022 Dividend(%) 200

Announcement Date 17-Aug-2021 Ex Dividend Date 17-Aug-2021 Dividend(%) 200

Announcement Date 29-Jul-2020 Ex Dividend Date 29-Jul-2020 Dividend(%) 200

Announcement Date 31-Jul-2019 Ex Dividend Date 31-Jul-2019 Dividend(%) 200

Announcement Date 18-Jul-2018 Ex Dividend Date 18-Jul-2018 Dividend(%) 200

Announcement Date 19-Jul-2017 Ex Dividend Date 19-Jul-2017 Dividend(%) 200

Announcement Date 21-Jul-2016 Ex Dividend Date 21-Jul-2016 Dividend(%) 200

Announcement Date 14-Jul-2015 Ex Dividend Date 14-Jul-2015 Dividend(%) 200

Announcement Date 16-Jul-2014 Ex Dividend Date 16-Jul-2014 Dividend(%) 200

Announcement Date 16-Jul-2013 Ex Dividend Date 16-Jul-2013 Dividend(%) 200

Announcement Date 18-Jul-2012 Ex Dividend Date 18-Jul-2012 Dividend(%) 200

Announcement Date 18-Jul-2011 Ex Dividend Date 18-Jul-2011 Dividend(%) 200

Announcement Date 21-Jul-2010 Ex Dividend Date 21-Jul-2010 Dividend(%) 200

Announcement Date 08-Jul-2009 Ex Dividend Date 08-Jul-2009 Dividend(%) 200

Announcement Date 07-Jul-2008 Ex Dividend Date 07-Jul-2008 Dividend(%) 200

Announcement Date 22-Mar-2007 Ex Dividend Date 22-Mar-2007 Dividend(%) 200

Bonus

No Bonus has been declared by NOVARTIND

Splits

No Split has been declared by NOVARTIND

Others

Ex-Rights Date 07-Dec-2017 Premium(Rs.) Ratio

Ex-Rights Date 21-Jul-2016 Premium(Rs.) Ratio

Novartis India Ltd Peer Comparison

Shows key financial metrics for the company and its peers

This section compares Novartis India Ltd with leading peers in the banking sector based on key metrics such as market capitalization, 1-year return, P/E (TTM), and PB ratio. It helps investors evaluate Novartis India Ltd's relative performance and valuation against major competitors.

Stock Name Alembic Ltd ₹99.61 (-0.18%) M. Cap (Cr) 25.58 1 Yr Return (%) -27.10% P/E (TTM) 8.08 PB Ratio 1.09

Stock Name Solara Active Pharma Sciences Ltd ₹565.05 (+0.42%) M. Cap (Cr) 20.43 1 Yr Return (%) -30.70% P/E (TTM) 392.16 PB Ratio 2.30

Stock Name Indoco Remedies Ltd ₹260.95 (-1.32%) M. Cap (Cr) 24.07 1 Yr Return (%) -17.03% P/E (TTM) -21.78 PB Ratio 2.21

Stock Name Novartis India Ltd ₹672.25 (-2.48%) M. Cap (Cr) 16.60 1 Yr Return (%) -1.49% P/E (TTM) 19.26 PB Ratio 2.81

Stock Name Amrutanjan Health Care Ltd ₹707.50 (-0.08%) M. Cap (Cr) 20.45 1 Yr Return (%) -4.10% P/E (TTM) 37.51 PB Ratio 6.26

Stock Name Windlas Biotech Ltd ₹869.85 (-5.74%) M. Cap (Cr) 18.33 1 Yr Return (%) -22.92% P/E (TTM) 27.08 PB Ratio 3.87

Stock Name Shukra Pharmaceuticals Ltd ₹40.97 (+1.99%) M. Cap (Cr) 17.94 1 Yr Return (%) +491.20% P/E (TTM) 177.28 PB Ratio 33.05

Novartis India Ltd Cash Flow

Cash flow data provides a view of how money is generated and spent by Novartis India Ltd, across its operating activities, investing activities, and financing activities.

PARTICULARS Operating Activities Mar 2025 74.57 Mar 2024 113.40 Mar 2023 44.80 Mar 2022 38.67 Mar 2021 -69.21

PARTICULARS Investing Activities Mar 2025 -3.31 Mar 2024 33.13 Mar 2023 -153.25 Mar 2022 87.04 Mar 2021 95.16

PARTICULARS Financing Activities Mar 2025 -64.15 Mar 2024 -120.99 Mar 2023 -30.48 Mar 2022 -35.63 Mar 2021 -36.80

PARTICULARS Net Cash Flow Mar 2025 7.11 Mar 2024 25.54 Mar 2023 -138.93 Mar 2022 90.08 Mar 2021 -10.85

Novartis India Ltd Shareholding Pattern

This shows the ownership breakdown of Novartis India Ltd, highlighting participation from Foreign Institutional Investors (FII), Mutual Funds, Public, Other Institutions, and Promoters.

Promoter 70.68%

Public 28.61%

Other Institutions 0.53%

FII 0.19%

Mutual Funds null%

About Novartis India Ltd

Novartis India Limited (NIL) is a subsidiary of Swiss giant Novartis, the world's second largest pharmaceutical company was incorporated on 13 December 1947. The Company is engaged in manufacturing and marketing of drugs, pharmaceutical products and formulations for consumer healthcare and animal healthcare; it operates into four segments such as Pharmaceuticals, Generics, Over the Trade Counter and Animal Health. The origin of Novartis is linked to the origin of three distinct companies namely Geigy, Ciba, and Sandoz. The history of Geigy goes back to the middle of the 18th century, Ciba was founded around 1860, and Sandoz was set-up in 1886. In 1970 Ciba and Geigy merged to form Ciba-Geigy Ltd. Sandoz and Ciba-Geigy Ltd continued as separate entities for the next 25 years. In 1996, in one of the largest corporate mergers in history Sandoz and Ciba-Geigy Ltd. joined to form Novartis. In the year 1998, the company had set-up the Novartis Institute for Functional Genomics. During the year 2000, Novartis acquired the products Famvir and Vectavir/Denavir from SmithKline Beecham also in the same year, the company started to provide treatment to leprosy patients worldwide through World Health Organisation (WHO). Also in 2000, NIL had started JEET (Joint Effort to Eradicate Tuberculosis) with the aim of increasing awareness among TB patents and to involve doctors more actively in the fight against disease. After a year, Novartis Respiratory Research Centre, the largest of its kind in the world, was opened in Horsham (UK) in 2001 and also during the same year Novartis had entered into a partnership with the WHO to stem the spread of malaria in areas of the world were the diseases in endemic. The Glivec, a drug was launched by the company in April of the year 2002 in India. The Company bagged TERI corporate social responsibility award for the year 2002-03. Novartis united its generics businesses under one single global brand in the name of Sandoz during the year 2003 and also in the same year, the company was granted Exclusive Marketing Rights (EMR) for Glivec. In the year of 2005, the company and Astex Therapeutics formed an alliance to focus on novel cell cycle anti-cancer drugs and also NIL had debuted Citro-macalvit & Trioptal as new products for the year.During the year 2006 alone Novartis had spent about USD 755 million on research into neglected diseases and various patient-access programs. In August of the same year 2006, the company had filed a petition in the Madras High Court challenging the rejection of the Glivec patent and the same petition was dismissed by the Madras high court in August of the year 2007. In the identical year of 2007, NIL sold its Medical Nutrition business to Nestle. The Company had launched a new marketing initiative on National scale in September of the year 2008 named Arogya Parivar targeting the healthcare needs of villagers. New products and line extensions introduced during the period 2009-10 were Relmus , Coderan for Pain & Inflammation, Vinlep for Epilepsy and Givec HGC 100 mg for Oncology. Otrivin was re-launched as an OTC remedy in a new spray format and positioned as a convenient alternative to tablets.During the period 2013-14, the Company signed a Distribution Agreement with Nutri-Ad International NV, Belgium, for marketing and distribution of their poultry feed supplements in India and started distributing Adimix 30 Coated, Eurotiox 32 Premix, Salmonil Dry, Toxynil Dry and Nutrilac IGA. The Company also signed a Marketing and Distribution Agreement with Johnson and Johnson Limited, India, for marketing and distribution of their Ethicon sutures under the brand names Mersutures Catgut 1, Ethilon Nylon and Mersilk Silk for veterinary use in the cattle and canine segments.The Company launched Voveran maxxgel TM and a new version of Voveran@1ml in 2019.

Chairman (Non-Executive)

C Snook

Registered office The Inspire BKC Part 601 & 701, Bandra Kurla Complex Bandra(E), Mumbai, Maharashtra, 400051

FAX :91-022-50243000

Background

Incorporation Year 1947

Face Value ₹5.00

Market Lot 1

Novartis India Ltd Latest News

VIEW MORE NEWS

FAQs on Novartis India Ltd